Bedside evaluation of thienopyridine antiplatelet therapy

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732.
No abstract available

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / physiology
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Clinical Trials as Topic
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Drug Resistance
  • Drug Therapy, Combination
  • Humans
  • Mass Screening
  • Myocardial Infarction / therapy
  • Nephelometry and Turbidimetry
  • Piperazines / administration & dosage
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Count
  • Platelet Function Tests / instrumentation
  • Platelet Function Tests / methods*
  • Point-of-Care Systems* / trends
  • Prasugrel Hydrochloride
  • Prodrugs / pharmacokinetics
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Thiophenes / administration & dosage
  • Thiophenes / pharmacology
  • Thiophenes / therapeutic use
  • Thrombelastography
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology*
  • Ticlopidine / therapeutic use
  • United States

Substances

  • P2RY12 protein, human
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Thiophenes
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Prasugrel Hydrochloride
  • Ticlopidine
  • Aspirin